Latest Articles
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? - Oncology Nursing News
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? Oncology Nursing News
Published: Jan. 14, 2026, 7:32 p.m.
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity TipRanks
Published: Jan. 14, 2026, 4:33 p.m.
Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma - springermedicine.com
Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma springermedicine.com
Published: Jan. 14, 2026, 6:02 a.m.
ASCO 2025: key highlights in endometrial cancer - springermedicine.com
ASCO 2025: key highlights in endometrial cancer springermedicine.com
Published: Jan. 13, 2026, 5:23 a.m.
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer - The ASCO Post
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer The ASCO Post
Published: Jan. 12, 2026, 6:10 p.m.
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer - Targeted Oncology
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer Targeted Oncology
Published: Jan. 11, 2026, 4:14 p.m.
‘Guiding Light’ Soap Opera Actress Beth Chamberlin, 62, Says She Received a Hysterectomy After Endometrial Cancer Diagnosis – ‘I Didn’t Tell Anyone, Not Even My Family’ Until Now - SurvivorNet
‘Guiding Light’ Soap Opera Actress Beth Chamberlin, 62, Says She Received a Hysterectomy After Endometrial Cancer Diagnosis – ‘I Didn’t Tell Anyone, Not Even My Family’ Until Now SurvivorNet
Published: Jan. 10, 2026, 5:07 p.m.
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - Defense World
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan Defense World
Published: Jan. 10, 2026, 6:12 a.m.
Endometrial Cancer: Evaluating Platinum Re-Challenge Strategies Through the ECHO-EU Lens - OncLive
Endometrial Cancer: Evaluating Platinum Re-Challenge Strategies Through the ECHO-EU Lens OncLive
Published: Jan. 9, 2026, 8:25 p.m.
Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities - OncLive
Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities OncLive
Published: Jan. 9, 2026, 2:17 p.m.
Link copied to clipboard!